Tarik Regad

Tarik Regad

Senior Research Fellow

School of Science & Technology

Staff Group(s)
Bioscience

Role

Dr Tarik Regad is a Senior Research Fellow in Molecular and Cellular Tumour Biology and his research focuses on investigating the role of cancer stem cells in cancer initiation, invasion and metastasis. He is also involved in delivering lectures and practical sessions on cancer and cancer stem cells for post-graduate level students within the module Biology of Disease.

Career overview

Dr Regad is a Doctor of Veterinary Medicine (DvetMed). He undertook his MSc, MRes and PhD at the University Paris VII (Denis Diderot) before joining the Gurdon Institute at the University of Cambridge (UK) as a Research Associate. In 2006, he moved to the MRC Toxicology Unit (University of Leicester) to undertake a position as a Career Development Fellow. He joined NTU in 2010 as a Lecturer/Senior Lecturer in Biosciences and he is now working as a Senior Research Fellow at the John van Geest Cancer Research Centre.

Research areas

Cancer stem cells (CSCs) are responsible for cancer initiation, invasion and metastasis in patients who were subjected to cancer therapies such as chemotherapy or radiotherapy. Therefore, the major challenges facing the cancer scientific community reside in identifying those malignant cells and develop therapies to target them. His projects are carried out at the John van Geest Cancer Research Centre and focus on:

  • Identifying tissue specific CSCs
  • Identifying CSCs specific biomarkers
  • Developing CSCs targeting strategies (Antibody therapy, Nanotechnology-based Trageting, Chemical therapy, Immunotherapy)
  • Investigating the molecular and cellular processes involved in cancer invasion and metastasis.

Opportunities arise to carry out postgraduate research towards an MPhil / PhD in the areas identified above. Further information may be obtained on the NTU Research Degrees website https://www.ntu.ac.uk/research/research-degrees-at-ntu.

A programme of fully-funded PhD studentships for UK, EU or international students at NTU is now open for application until the 25th February 2019.

Sponsors and collaborators

Recent research has been funded by

His collaborations involve several clinicians and scientists at national and international levels.

Publications

Selected Publications:

MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer. Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T. Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.

Targeting cellular pathways in glioblastoma multiforme. Pearson JRD, Regad T. Signal Transduct Target Ther. 2017 Sep 29;2:17040. doi: 10.1038/sigtrans.2017.40. eCollection 2017. Review.

A promyelocytic leukemia protein-thrombospondin 2 axis and the risk of relapse in neuroblastoma. Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Le Bras M, Burns A, Saunders N, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A and Salomoni P, Clinical Cancer Research, 2016, 22 (15)

Cytoplasmic PML promotes TGF-β-associated epithelial–mesenchymal transition and invasion in prostate cancer. Buczek ME, Miles AK, Green W, Johnson C, Boocock DJ, Pockley AG, Rees RC, Hulman G, Van Schalkwyk G, Parkinson R, Hulman J, Powe DG and Regad T, Oncogene, 2015

Targeting RTK signaling pathways in cancer., Cancers. Regad, T, Cancers, 2015, 7 (3), 1758-1784

The helicase HAGE prevents interferon-a-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1. Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC and Regad T, Cell Death and Disease, 2014, 5 (2)

The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SEB, Regad T, Journal of Biological Chemistry, 2012, 287 (17), 13633-13643

The tumour suppressor Pml regulates cell fate in the developing neocortex. Regad T, Bellodi C, Nicotera P and Salomoni P, Nature Neuroscience, 2009, 2 (2), 132-40

See all of Tarik Regad's publications...

Press expertise

  • Stem cells
  • Cancer stem cells
  • Cancer therapies (chemical and monoclonal antibody targeting)
  • Cancer initiation and progression (invasion and metastasis)